Pro00022491 - Amgen 102/Avastin

Clinical Trials for Adults | Phase II Study to Evaluate the Efficacy and Safety of AMG 102 and Avastin in Subjects with Recurrent Malignant Glioma


  • To assess the response rate of AMG 102 (C-Met inhibitor) and Avastin (anti-VEGF) treatment in subjects with advanced malignant glioma
  • To estimate overall survival and 6-month progression-free survival rates in this population 
  • To assess the safety in this population

Eligibility, Inclusion

  • Patients must have recurrent histologically confirmed diagnosis of WHO grade IV malignant glioma (glioblastoma multiforme or gliosarcoma) with no more than 3 prior progressions
  • Age ≥ 18 years
  • Karnofsky ≥ 60%
  • At least 4 weeks between either prior tumor biopsy or prior major surgical procedure and study enrollment
  • Measurable disease with no CNS hemorrhage as assessed by MRI or CT scan
  • Lab parameters that meet eligibility criteria – CBC with diff, CMP, UA
  • If sexually active, patients will take contraceptive measures for the duration of treatment

Exclusion Criteria

  • Pregnancy or breast-feeding
  • Baseline ECG with QTc > 0.45 second
  • Co-medication that may interfere with study results; e.g. immuno-suppressive agents other than corticosteroids
  • Thrombosis or vascular ischemic events within the last twelve months, such as deep venous thrombosis, pulmonary embolism, transient ischemic attack, cerebral infarction, or myocardial infarction
  • Active infection requiring IV antibiotics 7 days before enrollment
  • History of central nervous system bleeding as defined by stroke or intraocular bleed (including embolic stroke) within 6 months before enrollment
  • Evidence of acute intracranial hemorrhage; except for subjects with stable grade 1 hemorrhage
  • Less than 12 weeks from radiation therapy, unless progressive disease outside of the radiation field or 2 consecutive scans or histopathologic confirmation
  • Treated previously with any c-Met or HGF targeted therapy
  • Treated previously with VEGF or VEGFR therapies, including antibodies and tyrosine kinase inhibitors
  • Treated with thalidomide or tamoxifen within 1 week before enrollment or has not recovered from the toxic effects of such cancer therapy
  • Treated with immunotherapeutic agents, vaccines, or MAb therapy within 4 weeks before enrollment or have not recovered from the toxic effects of such cancer therapy
  • Treated with alkylating agents within 4 weeks before enrollment or has not recovered from the toxic effects of such cancer therapy
  • Treated with chemotherapy (non-alkylating agents) within 2 weeks before enrollment or has not recovered from the toxic effects of such cancer therapy
  • Plans to receive surgery, radiation therapy or other elective surgeries during the course of the study
  • Concurrent severe and/or uncontrolled medical disease (e.g. uncontrolled diabetes, congestive cardiac failure, myocardial infarction within 6 months before enrollment) that could compromise participation in the study
  • Concurrent or prior (within 7 days of enrollment) anticoagulation therapy, except: Use of low dose coumadin-type anticoagulants (≤ 2 mg PO QD) low molecular weight heparins (LMWH), e.g. Enoxaparin sodium (Lovenox) and unfractionated heparin for prophylaxis against central venous catheter thrombosis is allowed
  • Grade 2 or greater peripheral edema or effusion (pleural, pericardial, or ascites)
  • Inability to comply with study and/or follow-up procedure
  • Current, recent (within 4 weeks of the first infusion of this study), or planned participation in an experimental drug study

Avastin-Specific Exclusion Criteria (Subjects meeting any of the following criteria are ineligible for study entry)

  • Inadequately controlled hypertension (defined as systolic blood pressure >150 mmHg and/or diastolic blood pressure > 100 mmHg)
  • Prior history of hypertensive crisis or hypertensive encephalopathy
  • New York Heart Association (NYHA) Grade II or greater congestive heart failure
  • History of myocardial infarction or unstable angina within 6 months prior to Day 1, the day protocol therapy starts
  • History of stroke or transient ischemic attack within 6 months prior to Day 1
  • Significant vascular disease (e.g. aortic aneurysm, requiring surgical repair or recent peripheral arterial thrombosis) (within 6 months prior to Day 1)
  • History of hemoptysis ( 1/2 teaspoon of bright red blood per episode) within 28 days prior to Day 1
  • Evidence of bleeding diathesis or significant coagulopathy (in the absence of therapeutic anticoagulation)
  • Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to Day 1
  • Core biopsy or other minor surgical procedure, excluding placement of a vascular access device, within 7 days prior to Day 1
  • Serious, non-healing wound, active ulcer or untreated bone fracture
  • Proteinuria as defined by > +1 on urinalysis dipstick
  • Known hypersensitivity to any component of Avastin

Treatment Plan

  • All treatments at Duke
  • Infusions will be every other week (days 1,15 and 29 of each 42 day of cycle)
  • Amgen 102 is provided free by Amgen
  • Lab work  every other week
  • Return to clinic every 6 weeks and with MRI and ECG
  • May receive treatment until tumor progresses, have too many toxicities, or want to come off study 

This article comes from The Preston Robert Tisch Brain Tumor Center at Duke
The URL for this story is: